VISIBILITY ILIAC was conducted to confirm the safety and effectiveness of primary stenting using the Visi-Pro™ balloon-expandable peripheral stent system for the treatment of lesions in the common and external iliac arteries. Noteworthy points about the study:
- 75 subjects enrolled
- ≥ 50% stenosis, restenosis, or occlusion
- Target lesion length ≤ 10 cm
- Target vessel diameter is ≥ 5.0 cm and ≤ 10 cm
Results of VISIBILITY ILIAC:
- Nine-month MAE rate of 4.0%
- 4.0% clinically driven TLR
- 0.0% periprocedural death
- 0.0% in-hospital MI
- 0% amputation of treated limb
- Nine-month primary patency rate of 95.8%
Read more about the VISIBILITY ILIAC clinical study in a published, peer-reviewed journal:
Results From the VISIBILITY Iliac Study: Primary and Cohort Outcomes at 9 Months
Rundback, et al. J Endovascular Therapy, 2017 Feb: 1-7.